Rucaparib
Products Rucaparib was approved in tablet form in the United States in 2016, in the EU in 2018, and in many countries in 2020 (Rubraca). Structure and properties Rucaparib (C19H18FN3O, Mr = 323.4 g/mol) is present in the drug as rucaparibcamsylate, a white to slightly yellow powder. Effects Rucaparib has antitumor and cytotoxic properties. The … Rucaparib
